A Phase 2 interventional study of Brimonidine and Brimonidine Mono Therapy in Dry Eye, sponsored by Ocugen. Completed at 3 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-06.
Sponsored by Ocugen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 544 studies in Dry Eye Syndromes with a site in United States — 52 open to participants now, 63 under way, 3 of them phase 3. Dry Eye Syndromes · United States.
Among the 544 studies in Dry Eye Syndromes with a site in United States, this one is the 203rd largest by enrollment of the 473 interventional ones that give a count, is one of 16 that started in 2017, is one of 97 in phase 2, and was the 248th registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.
Browse Dry Eye Syndromes studies →52 of the 544 studies in Dry Eye Syndromes with a site in United States are open now. Recruiting first, the newest first:
Scott & Christie and Associates, PC · Sites in United States
Ages 18+
Bausch & Lomb Incorporated · Sites in United States
Ages 18+
Alcon Research · Sites in United States
Ages 22+ · Healthy volunteers
Cleveland Eye Clinic · Sites in United States
Ages 50–75
Eye Research Associates, LLC · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
544 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 36 · Phase 2 132 · Phase 3 95 · Phase 4 116
First in 1997; this study’s year is marked. 16 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 84 is above the median of 60 across 1,129 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 60 across the 473 interventional studies, 80 across the 64 observational. Of the 439 that completed or were terminated, 232 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
330 of 544 have an industry lead sponsor. The 10 most frequent:
Ocugen is the lead sponsor of 12 studies on the registry; 2 are open to participants now.
Ocugen has 2 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
31 of the studies in Dry Eye Syndromes with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07548632Phase 3OculisA Clinical Study Evaluating Licaminlimab for Dry Eye Disease | 2026-12 |
| NCT07281950Center for Sight Las VegasInvestigator Initiated Trial Using Dry Eye Surveys to Evaluate and Better Understand FDA Approved Acoltremon Treatment for Dry Eye Disease in Real World Treatment Settings (DESERT) | 2026-11-30 |
| NCT07566975Neuro-Ophthalmology of TexasReal-World Assessment of VEVYE® for Short-Term Symptom and Sign Improvement of Dry Eye Disease in a Neuro-Ophthalmology Clinic: A 6-Month Prospective Observational Study | 2026-11-30 |
| NCT07768735Alcon ResearchUNITY DX Cornea Study | 2026-12 |
| NCT07928986Cleveland Eye ClinicA Multi Center Evaluation of TearCare on Surgical Measurements Before Cataract Surgery | 2026-12 |
Add all 31 to your calendar (.ics) → With an account.
Among the 544 studies in Dry Eye Syndromes with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the tolerability and preliminary efficacy of Brimonidine eye drops (with and without corticosteroid eye drops) for the treatment of Dry Eye Disease (DED).
Subjects will assess their tolerance to the administration of the study drug, utilizing a Visual Analog Scale (VAS). The VAS is a 100-mm horizontal line with verbal descriptors at either end. The VAS ratings will be completed after administration of the study drug on Day 1 (post-dose), Day 28, Day 56, Day 84, and Day 105. Subjects will place a single slash mark across the horizontal line between the end labeled "completely intolerable" (0 mm) and "easily tolerable" (100mm).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Objective evidence of DED in at least one eye by having 2 or more of the following 4 signs in the same eye at Screening and Baseline (Day 1) visits:
i. Conjunctival staining at >/= 1 (out of a possible score of 6 per eye) ii. Corneal staining at >/= 2 (out of a possible score of 15 per eye) iii. Noninvasive Tear Break-Up Time (NITBUT) at \</= 7 seconds iv. Schirmer test at \<10mm in 5 minutes
Women who satisfy one of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Combination Therapy: brimonidine (0.2%) administered as eye drops, followed by corticosteroid eye drops, two times a day (BID) for 12 weeks
Drug: Brimonidine · Drug: Corticosteroid Eye Drop
Monotherapy: brimonidine (0.2%) administered as eye drops followed by placebo, two times a day (BID) for 12 weeks
Drug: Brimonidine Mono Therapy
Placebo: sodium carboxymethylcellulose (0.25%) administered as eye drops followed by a second application, two time a day (BID) for 12 weeks
Drug: sodium carboxymethylcellulose
Two products delivered in sequence twice daily.
Brimonidine given twice daily along with placebo drops
Placebo given twice daily.
Eye drop to be administered after Brimonidine in treatment arm 1
Tolerance of Test Substance Visual Analogue Scale (VAS) Score
Participants assessed their tolerance to the administration of the study drug, utilizing a VAS. The VAS is a 100-mm horizontal line with verbal descriptors at either end. Participants placed a single slash mark across the horizontal line between the end labeled "completely intolerable" (0 mm) and "easily tolerable" (100mm).
Time frame: Days 1, 28, 56, and 84
| Milestone | Brimonidine and Corticosteroid Combination Therapy | Brimonidine Monotherapy | Placebo |
|---|---|---|---|
| Started | 29 | 28 | 27 |
| Received at least 1 study treatment | 29 | 28 | 27 |
| Completed | 28 | 26 | 25 |
| Not completed | 1 | 2 | 2 |
| Withdrew: Adverse event | 1 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 |
Participants assessed their tolerance to the administration of the study drug, utilizing a VAS. The VAS is a 100-mm horizontal line with verbal descriptors at either end. Participants placed a single slash mark across the horizontal line between the end labeled "completely intolerable" (0 mm) and "easily tolerable" (100mm).
| score on a scale | Brimonidine and Corticosteroid Combination Therapy | Brimonidine Monotherapy | Placebo |
|---|---|---|---|
| Day 1 | 82.1 (74.5 to 89.8) | 87.0 (82.2 to 91.9) | 95.0 (92.3 to 97.7) |
| Day 28 | 91.1 (86.6 to 95.5) | 87.4 (82.5 to 92.3) | 88.2 (82.7 to 93.7) |
| Day 56 | 92.0 (88.3 to 95.8) | 85.6 (80.6 to 90.7) | 91.0 (84.2 to 97.9) |
| Day 84 | 87.8 (82.2 to 93.5) | 85.9 (78.6 to 93.1) | 94.8 (91.6 to 98.1) |
Collected over Day 1 (post-dose) up to 105 Days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brimonidine and Corticosteroid Combination Therapy | 0/29 (0%) | 1/29 (3.4%) | 0/29 (0%) |
| Brimonidine Monotherapy | 0/28 (0%) | 0/28 (0%) | 0/28 (0%) |
| Placebo | 0/27 (0%) | 1/27 (3.7%) | 0/27 (0%) |
| Event | Brimonidine and Corticosteroid Combination Therapy | Brimonidine Monotherapy | Placebo |
|---|---|---|---|
| Knee operationSurgical and medical procedures | 0/29 | 0/28 | 1/27 |
| Benign prostatic hyperplasiaReproductive system and breast disorders | 1/29 | 0/28 | 0/27 |
Randomized population including all participants who were randomized to the treatment
| Age, Continuous(years) | Brimonidine and Corticosteroid Combination Therapy | Brimonidine Monotherapy | Placebo | Total |
|---|---|---|---|---|
| Mean | 62.1 ± 11.41 | 60.4 ± 13.88 | 59.2 ± 14.23 | 60.6 ± 13.09 |
| Sex: Female, Male(Participants) | Brimonidine and Corticosteroid Combination Therapy | Brimonidine Monotherapy | Placebo | Total |
|---|---|---|---|---|
| Female | 26 | 25 | 18 | 69 |
| Male | 3 | 3 | 9 | 15 |
| Ethnicity (NIH/OMB)(Participants) | Brimonidine and Corticosteroid Combination Therapy | Brimonidine Monotherapy | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 3 | 2 | 5 |
| Not Hispanic or Latino | 29 | 25 | 25 | 79 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Brimonidine and Corticosteroid Combination Therapy | Brimonidine Monotherapy | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 28 | 27 | 26 | 81 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2017 to primary completion in Mar 2018, 6 months.
Results were first posted in Jul 2022, 4 years 3 months after primary completion.
Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's 6 months is below that.
Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brimonidine
Ocugen